Actinium Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Actinium Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $81.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.03M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.14M | Mar 31, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $0 | Apr 12, 2012 |
| FY2011 | Dec 31, 2010 | $0 | Apr 12, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $0 | Apr 12, 2012 |
| FY2011 | Dec 31, 2010 | $0 | Apr 12, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.89M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($38.24M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($48.82M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($33.02M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($24.77M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($22.22M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($21.90M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($23.65M) | May 8, 2020 |
| FY2018 | Dec 31, 2017 | ($26.60M) | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | ($24.32M) | Mar 15, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.25M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($42.12M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($51.92M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($34.10M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($24.96M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($22.39M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($22.07M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($23.83M) | May 8, 2020 |
| FY2018 | Dec 31, 2017 | ($26.91M) | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | ($26.85M) | Mar 15, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.12M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $30.05M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $38.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $23.14M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $18.03M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $16.09M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $16.55M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $17.09M | May 8, 2020 |
| FY2018 | Dec 31, 2017 | $17.72M | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | $17.83M | Mar 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.58M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($33.07M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($47.34M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.64M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($20.87M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($21.62M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($21.46M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($20.57M) | May 8, 2020 |
| FY2018 | Dec 31, 2017 | ($21.55M) | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | ($20.79M) | Mar 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $11.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $153.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $366.0K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $133.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $253.0K | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $64.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $96.1K | May 8, 2020 |
| FY2018 | Dec 31, 2017 | $24.7K | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | $60.0K | Mar 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.78M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $76.90M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $81.45M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $114.19M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $80.39M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $66.40M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $11.67M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $14.89M | May 8, 2020 |
| FY2018 | Dec 31, 2017 | $18.34M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $22.53M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.94M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $44.14M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $45.07M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $47.71M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $6.84M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.08M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $6.03M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.08M | May 8, 2020 |
| FY2018 | Dec 31, 2017 | $4.67M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $4.52M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.83M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $32.76M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $36.38M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $66.48M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $73.55M | Mar 29, 2024 |
| FY2021 | Dec 31, 2020 | $61.32M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $5.64M | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | $8.81M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $13.67M | May 8, 2020 |
| FY2018 | Dec 31, 2016 | $18.01M | Mar 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($409.71M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($375.83M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($337.58M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($288.77M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($255.75M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($230.97M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($208.76M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($186.86M) | May 8, 2020 |
| FY2018 | Dec 31, 2017 | ($163.15M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($136.55M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.00M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $72.90M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $76.68M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $108.91M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $77.83M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $63.56M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $9.25M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $13.67M | May 8, 2020 |
| FY2018 | Dec 31, 2017 | $17.40M | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | $20.52M | Mar 15, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31.20M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 31.20M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 27.63M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 25.67M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 22.14M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 17.53M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | 5.49M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 115.70M | May 8, 2020 |
| FY2018 | Dec 31, 2017 | 80.07M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 55.80M | Mar 16, 2018 |